Good day, ladies and gentlemen, and welcome to the Xenon Third Quarter 2017 Financial Results. [Operator Instructions]. As a reminder, this conference call's being recorded. I would now like to turn the conference over to Jodi Regts. Ma'am, you may begin.

Thank you. This afternoon Xenon announced on our Q3 conference call that GlobeNewswire was experiencing severe technical difficulties, and as a result by the start of the conference call, Xenon's news release has not yet crossed the wires. Because of this, we opted to delay the conference call and wait for the news release to be broadly distributed. This recording captures the prepared remarks of senior management for Xenon's Q3 conference call. And this webcast will be archived on our website. This webcast will discuss Xenon's financial and operating results for the third quarter ended September 30, 2017. Joining me on today's call are Dr. Simon Pimstone, Xenon's President and Chief Executive Officer; and Ian Mortimer, Xenon's Chief Financial Officer and Chief Operating Officer. Following this introduction, Simon will provide perspective on Xenon's progress, and then, Ian will review our financial results. Please be advised that during this call, we will make a number of statements that are forward-looking, including statements about the sufficiency of our capital position to execute on our business objectives and our ability to operate in a capital-efficient manner, our expectations regarding the sufficiency of our cash to fund operations into the first quarter of 2019, the timing of IND or IND equivalent submissions with regulatory agencies, the initiation of future clinical trials, the potential efficacy, future development plans and commercial potential of our and our collaborators product candidates, the timing of and results from ongoing clinical trials and preclinical development activities, our ability to achieve certain milestones, in both our proprietary and partner development programs, the plans of our collaboration partners and their interactions with regulatory agencies, the results of our research and development efforts and the status and timing of additional product candidates and related-development activities. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond our control, including the risks and uncertainties described from time to time in our SEC filings. Our results may differ materially from those projected on today's call. We undertake no obligation to publicly update any forward-looking statement. Today's press release summarizing our third quarter 2017 results and the accompanying quarterly report on Form 10-Q are now available under the Investors section of our website at www.xenon-pharma.com and filed with the SEC and on SEDAR. Now I'd like to turn the call over to Simon.

Thanks, Jodi. As we go closer to the end of 2017, we are highly encouraged by the progress we have made in expanding and advancing Xenon's proprietary pipeline. We continue to implement our strategy to leverage our expertise around CNS-based ion channel drug development and have sharpened our focus on advancing novel antiepileptic drugs or AEDs. In our call today, I'll begin by providing a brief overview of our partnered programs and then concentrate on 2 of our proprietary assets, XEN1101 and XEN901, both in development for the potential treatment of epilepsy. We are currently in discussions with our partner Teva to discuss the path forward for TV-45070 program, a topical pain sodium channel inhibitor that we licensed to Teva for the treatment of neuropathic pain. We will provide updates when a decision has been reached on a plan. Turning to our partnership with Genentech. Today we disclosed that GDC-0310, will not enter a Phase II clinical trial in the first quarter of 2018. This change in guidance was predicated upon new data from preclinical toxicology studies with GDC-0310. Further preclinical studies are now underway to better understand these findings. Updated guidance around GDC-0310 will be revised once the preclinical studies are completed. As a reminder, Genentech is responsible for all development decisions and for all costs under this collaboration. Therefore, we can only communicate the information that is provided to us by Genentech. Genentech remained keenly focused on GDC-0310 in the broader Nav1.7 program. While we are disappointed in this delay, we are focusing all of our resources on our proprietary programs of which we maintain complete control. We intend to drive our epilepsy programs forward in order to create imported value-creating inflection points for Xenon. We're also engaged in the second collaboration with Genentech centered on pain genetics…

Thanks, Simon. I'm going to focus my comments on the key aspects of our third quarter financial results, including our current cash position and cash runway as well as operating expenses. Cash and cash equivalents and marketable securities as of September 30, 2017, were $43.8 million, compared to $64.1 million as of December 31, 2016. Based on our current assumptions, which include fully supporting the planned clinical development of XEN1101 and XEN901 as previously guided, we anticipate having sufficient cash to fund operations into the first quarter of 2019, excluding any revenue generated from existing partnerships or potential new partnering arrangements. Research and development expenses for the quarter were $7.2 million, compared to $6 million for the same period in 2016. The increase of $1.2 million was primarily attributable to increased spending on the preclinical discovery and other internal programs as well as XEN1101, and partially offset by a decrease in XEN801 expenses, which is no longer being developed and a decrease in collaboration expenses. General and administrative expenses for the quarter were $1.7 million, compared to $1.8 million for the same period in 2016. This decrease of $0.1 million is primarily attributable to the fair value adjustment on liability classified stock options. Other income for the quarter was $0.9 million, compared to other expense of $0.4 million for the same period in 2016. The change was primarily driven by an increase in unrealized foreign exchange gains arising from the translation of Canadian denominated balances to U.S. dollars. Net loss for the quarter was $7.7 million, unchanged from the same period in 2016, due to lower revenue, higher R&D expenses, partially offset by higher unrealized foreign exchange gains recorded in the quarter ended September 30, 2017. So in summary, as we continue to build an innovative portfolio of antiepileptic drugs, we plan to efficiently and strategically manage our resources and cash runway. And looking ahead, we envision our 2 proprietary epilepsy programs advancing through clinical development, and both in Phase II clinical trials by the end of 2018, if supported by the data. We are excited by this work within our proprietary programs and we look forward to keeping you updated on our progress. So thank you for joining us on the call today, and we look forward to providing updates on our progress throughout the remainder of the year. Operator, we can now end the call.

Ladies and gentlemen, thank you for participating in today's conference. This does conclude the program, and you may all disconnect. Everyone, have a great day.